Ampersand Capital Partners acquires Biologos

Ampersand Capital Partners announced the acquisition of Biologos LLC. The partnership with Ampersand will include investments to expand Biologos’ capabilities, product offerings, and geographic reach to support its cell and gene therapy, biopharmaceutical, tissue processing, and animal health customers globally.

Biologos CEO Tony Bazarko comments, “This is an exciting time at Biologos as we have experienced impressive growth thanks to our team’s ability to provide high-quality standard and custom biologics solutions for our customers. Ampersand’s deep industry expertise, broad network, and capital resources will enable Biologos to accelerate its growth strategy through the development of new products and its expansion into new markets.”

As part of the transaction, Frank Witney, an industry veteran and Ampersand Operating Partner, has been named Chairman of Biologos, with Eric Lev and Mario Reto of Ampersand also appointed as new Board Members.

Eric Lev adds, “The investment in Biologos aligns well with Ampersand’s strategy of supporting growth-oriented life science organizations with a history of product innovation and customer excellence. Under Tony’s leadership, we are confident in the team’s ability to continue its strong momentum and look forward to partnering together on this growth journey.”
MB Bureau